MYL News and Press, Mylan N.V.

Pfizer (PFE) completes the deal to spin off its Upjohn business and combine it with Mylan NV (MYL) to form Viatris (VTRS), which will start trading tomorrow under the ticker symbol VTRS.Pfizer stockholders received ~0.124079 shares of Viatris common stock for every one share of Pfizer common ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Mylan has undergone a contraction in valuation over the last 5 years, and the upcoming Viatris merger comes at a crucial time for the company. The deal structure means Viatris stock looks attractive on 2021 pro forma multiples of ~5x-8x EV/EBITDA. Short interest has peaked at ~81%...

Teva's revenues disappointed, but this was likely due to COVID-dependent market volatility. In contrast, margins were up significantly, which should benefit long-term shareholders over time. The key issue holding back the stock right now is the opioid litigation, which is unlikely...

ProPhase's existing business is unexciting. COVID has been a tailwind. A pivot to diagnostics may work out, but has led to a ludicrous valuation. For further details see: Subject, Verb, COVID-19: ProPhase Doesn't Deserve Its Recent Share Price Increase

The following slide deck was published by Mylan N.V. in conjunction with their 2020 Q3 earnings call. For further details see: Mylan N.V. 2020 Q3 - Results - Earnings Call Presentation

Mylan N.V. (MYL) Q3 results:Revenues: $2,972.1M (+0.3%).Sales in Europe up 7%. Sales in North America down 5%.Net income: $185.7M (-2.2%); non-GAAP net income: $679.7M (+12.5%); EPS: $0.36 (-2.8%); non-GAAP EBITDA: $1,009.7M (+9.4%).Cash flow ops: $525.0M (+7.6%).No guidance provided.This is ...

Mylan (MYL): Q3 Non-GAAP EPS of $1.31 beats by $0.15; GAAP EPS of $0.36 misses by $0.12.Revenue of $2.97B (+0.3% Y/Y) misses by $30M.Non-GAAP gross margin of 55% vs. consensus of 53.1%.Press Release For further details see: Mylan EPS beats by $0.15, misses on revenue

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...